Navigation Links
Market Access and Pipeline Development – How Healthcare Modeling Can Make a Difference, a Pharmaceutical Market Strategy Webinar from Xtalks
Date:11/20/2013

(PRWEB) November 20, 2013

Executives at leading biopharma organizations are reengineering the way they develop and market drugs. They are doing this by making market access planning an integral part of their organization and incorporating clinical and economic benefit in product development and commercialization decisions. Changing demands in the healthcare system is changing how the industry assesses a product’s viability. Specifically, organization’s are now considering the economic benefit that can support the use of a particular drug/device in the context of its efficacy and competitive position. One specific approach that is being used is the application of economic and clinical outcomes models in early to mid-stage clinical development.

In this short, 30-minute webinar, attendees will learn how the Archimedes Model was applied by Eli Lilly and Company to prioritize early stage compounds for development. The following topics will be covered:

  • High level case study
  • Brief overview of the Archimedes Model
  • Detailed case study
  • Q&A

For more information about this online seminar or to register, go to http://xtalks.com/Healthcare-Modeling-and-Market-Access.ashx

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service provider
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
6. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
7. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
8. GeneLink Marketing Efforts Poised to Show Results
9. Animal Biotechnology - Technologies, Markets and Companies
10. Gene Therapy - Technologies, Markets and Companies
11. Biomarkers - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Pennsylvanie, 18 septembre 2014 Mapi, ... en 1974, a été depuis 40 ans ... évaluations cliniques traditionnelles par des évaluations recentrées ... sur les impacts économiques des traitements. ... A cours d,une récente conférence ...
(Date:9/18/2014)... expensive. Now a team led by an engineer at ... designs that will let scientists slash the cost of ... , Syringe pumps are used to dispatch precise amounts ... in a reaction. They can also cost hundreds or ... team of Michigan Tech students published the library of ...
(Date:9/18/2014)... Silicon-valley Electronic Data Capture (EDC) provider ... , the latest addition to Clinovo’s CRO Partnership Program. ... (CRO) Program, Clinovo further expands its global reach to ... training, we are now able to build studies on ... can also rely on Clinovo to fully support the ...
(Date:9/17/2014)... 17, 2014 A long-term retrospective study ... irradiation (APBI) via interstitial brachytherapy suggests that women ... nodes could be suitable to receive the treatment. ... place these patients in the "unsuitable" category for ... ASTRO meeting, Beaumont Health System,s Peter Y. ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Doing science just got cheaper -- and faster 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4
... DUBLIN, Ireland, January 9 Azur Pharma ... the exclusive U.S. marketing rights,for Niravam(R) (alprazolam ... Kemstro(TM) (baclofen,orally disintegrating tablets) and Fluxid(TM) (famotidine ... terms were not,disclosed. , ...
... The IN VIVO Blog , which provides news, insights and ... a Deal of the Year for 2008 -- ... than 2,500 reader votes were cast in this inaugural competition, ... the 13 nominees selected by The IN VIVO Blog,s writers ...
... MATK ) announced today that it will be ... The conference is being held January 14-15, 2009 at ... Point, California. Peter L. Buzy, Chief Financial Officer, and ... 2009 at 1:25 PM PT.A live audio webcast of Martek,s ...
Cached Biology Technology:Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB 2The IN VIVO Blog Selects First Annual 'Deal of the Year' 2
(Date:9/18/2014)... Elsevier, a world-leading provider of scientific, technical and ... Research Management Society (ARMS), recognized the academic research ... Scopus Young Researcher of the Year Awards. , ... National Convention Centre and in conjunction with the ... representing Australia,s and New Zealand,s scientific community. Guest ...
(Date:9/18/2014)... entire lives nestling in the protective tentacles of host ... sometimes travel hundreds of kilometres across the open ocean. ... has been predicted, this is the first time that ... has been observed. , Dr Steve Simpson, Senior Lecturer ... of Exeter, and colleagues from the Australian Research Council ...
(Date:9/17/2014)... EC-FP5 four-year project, delivering its first release in 2004. ... in several EC projects, as a part of the ... BON), to increase the general awareness of the work ... dissemination of the Fauna Europaea results, the ... e-Publishing tools to prepare data papers for all 56 ...
Breaking Biology News(10 mins):Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... Wash. -- A new study reveals how pollution causes ... Appearing in the Proceedings of the National Academy ... long-standing debate and reveal how pollution plays into climate ... the accuracy of weather and climate models. Researchers ...
... that protect it from insect damage has been grown in the ... are derived from a bacterium called Bacillus thuringiensis , these ... has been highly effective against the European corn borer, it has ... documented to show resistance to the Bt proteins. In a new ...
... impairment is a transitional stage between normal aging ... this transformation have yet to be studied. Dr. ... Technology, China constructed brain networks using resting-state functional ... (normal controls, patients with early mild cognitive impairment, ...
Cached Biology News:The lingering clouds 2The lingering clouds 3Scientists offer recommendations for delaying resistance to Bt corn in western corn rootworm 2